Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler

Arun Nair, Daniel Menzies, Martyn Barnes, Patricia Burns, Lesley McFarlane, Brian J. Lipworth

    Research output: Contribution to journalArticle

    17 Citations (Scopus)

    Abstract

    AIMS

    To compare the respirable dose delivery of the hydrofluroalkane fluticasone propionate (HFA-FP) via an optimally prepared Aerochamber Plus spacer (AP), via a Synchro-Breathe (SB) device, and pMDI Evohaler (EH).

    METHODS

    Seventeen mild to moderate asthmatics completed the study using a randomized, double-blind, double-dummy, three way crossover design. Single doses of placebo or HFA-FP 2.0 mg were administered via the EH, AP, and SB devices. The overnight urinary cortisol : creatinine ratio (OUCC) was measured at baseline and after each dose.

    RESULTS

    Significant suppression of OUCC occurred from baseline with AP and SB but not EH devices (geometric mean fold suppression, 95% CI): AP: 3.18 (2.29, 4.36), P < 0.001; SB: 1.79 (1.31, 2.40), P = 0.001; EH: 1.12 (0.69, 1.44), p = 0.37 (equating to 68%, 45% and 9% falls, respectively). Significant differences in OUCC between devices were as follows: (geometric mean fold difference, 95% CI): AP vs. EH. 2.83 (2.09, 3.82), P < 0.001; AP vs. SB: 1.78 fold (1.21, 2.60), P = 0.003; SB vs. EH: 1.59 (1.09, 2.31), P = 0.013 (equating to 65%, 44% and 37% differences, respectively).

    CONCLUSIONS

    The use of an optimally prepared AP spacer and breath actuated SB device, when compared with pMDI, significantly increased the respirable dose of HFA-FP.

    Original languageEnglish
    Pages (from-to)20-26
    Number of pages7
    JournalBritish Journal of Clinical Pharmacology
    Volume66
    Issue number1
    DOIs
    Publication statusPublished - Jul 2008

    Keywords

    • Adrenal suppression
    • Asthma
    • Fluticasone propionate
    • Spacer
    • Large volume spacer
    • Systemic bioactivity
    • Asthmatic patients
    • Lung delivery
    • Corticosteroids
    • Salbutamol
    • Inhalation
    • Formulations
    • Children

    Cite this